Vitura Health (ASX:VIT) said that its revenue and earnings before interest, taxes, depreciation, and amortization increased successively during each of February, March, and April, according to a Monday Australian bourse filing.
The firm's focus on integrating the recently acquired Candor Medical business drove both revenue and EBITDA improvement, while the results for the March quarter included the inclusion of the first full quarter of contribution from the recently acquired Releaf Group, in which Vitura holds a 50% interest, demonstrating growth in patient numbers and revenue.
The firm is forecasting that the total revenue for the fourth quarter will support an annualized revenue rate over AU$138 million, a rise of 11% on the same figure for fiscal 2024.
It forecasts that EBITDA for the fourth quarter on an annualized basis should deliver the 3% improvement in EBITDA margin in fiscal 2025 the firm set out in the strategy reset. The firm expects the EBITDA figure for fiscal 2025 should increase by around 20%, as compared to the prior financial year.
The company's shares were up almost 3% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。